



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE
DELLA RICERCA

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Boffa, G., Signori, A., Massacesi, L., Mariottini, A., Sbragia, E., Cottone, S., et al. (2023). Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. *NEUROLOGY*, 100(11), e1109-e1122 [10.1212/WNL.000000000206750].

Availability:

This version is available at: <https://hdl.handle.net/11585/913915> since: 2024-02-24

Published:

DOI: <http://doi.org/10.1212/WNL.000000000206750>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

1 **Autologous Hematopoietic Stem Cell Transplantation Reduces Disability Progression In Patients With**
2 **Secondary Progressive Multiple Sclerosis: Results From The Italian Multiple Sclerosis Register**

3

4 Boffa G*¹ MD, Signori A*² PhD, Massacesi L³ MD, Mariottini A³ MD, Cottone S⁴ MD, Amato MP⁵ MD,
5 Gasperini C⁶ MD, Moiola L⁷ MD, Meletti S⁸ MD, Brescia Morra V⁹ MD, Iaffaldano P¹⁰ MD, Salemi G¹¹
6 MD, Patti F¹² MD, Romeo M⁷ MD, De Luca G¹³ MD, Lus G¹⁴ MD, Zaffaroni M¹⁵ MD, Sola P¹⁶ MD,
7 Conte A¹⁷ MD, Pozzilli C¹⁸ MD, Aguglia U¹⁹ MD, Granella F²⁰ MD, Galgani S²¹ MD, Caniatti LM²² MD,
8 Lugaresi A²³ MD, Romano S²⁴ MD, Saccardi R²⁵ MD, Angelucci E²⁶ MD, Mancardi GL^{1,27} MD, Sormani
9 MP² PhD and Inglese M¹ MD, PhD on behalf of the Italian BMT-MS Study Group and the Italian MS
10 Register.

11

12 ** These two authors equally contributed to the work.*

13

14 ¹ Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health,
15 University of Genoa, San Martino Hospital, Genoa/Italy.

16 ² Biostatistics Unit, University of Genoa, Genoa/Italy.

17 ³ Department of Neurosciences Drugs and Child Health and Department of Neurology 2, Careggi
18 University Hospital, Florence, Italy

19 ⁴ Department of Neurology, Villa Sofia Hospital, Palermo/Italy.

20 ⁵ Department NEUROFARBA, Section Neurological Sciences University of Florence IRCCS Fondazione
21 Don Carlo Gnocchi, Florence, Italy

22 ⁶ Department of Neurology, Ospedale San Camillo-Forlanini, Roma/Italy.

- 23 ⁷ Department of Neurology, Vita-Salute San Raffaele University, San Raffaele Scientific Institute,
24 Milan/Italy.
- 25 ⁸ Department of neurology, S.Agostino Estense Hospital, Modena/Italy.
- 26 ⁹ Neurosciences and Reproductive and Odontostomatological Sciences, University "Federico II,"
27 Naples, Italy.
- 28 ¹⁰ Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo
29 Moro, Bari/Italy.
- 30 ¹¹ Unit of Neurology, Department of Biomedicine, Neurosciences and Advanced Diagnostics,
31 University of Palermo.
- 32 ¹² Department of Medical and Surgical Sciences and Advanced Technologies, AOU Policlinico-San
33 Marco, University of Catania, Catania/Italy.
- 34 ¹³ MS Centre, Neurology Unit, SS. Annunziata University Hospital, Chieti/Italy.
- 35 ¹⁴ University of Campania "Luigi Vanvitelli", Department of Advanced Medical and Surgical Sciences,
36 2nd Division of Neurology, Naples/Italy.
- 37 ¹⁵ Multiple Sclerosis Center, ASST della Valle Olona, Hospital of Gallarate, Gallarate/Italy.
- 38 ¹⁶ Neurology Unit, Azienda Ospedaliero-Universitaria of Modena, Modena/Italy.
- 39 ¹⁷ IRCCS Neuromed, Department of Human Neurosciences, Sapienza, University of Rome,
40 Pozzilli/Italy.
- 41 ¹⁸ Department of Human Neuroscience, Sapienza University, Rome/Italy.
- 42 ¹⁹ Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro/Italy.
- 43 ²⁰ Department of Neurology, University of Parma/Italy.
- 44 ²¹ Department of Neurosciences, San Camillo-Forlanini Hospital, Rome/Italy.

45 ²² Department of Neuroscience and Rehabilitation, Azienda Ospedaliero-Universitaria di Ferrara,
46 Ferrara/Italy.

47 ²³ IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia/Dipartimento di Scienze
48 Biomediche e Neuromotorie, Università di Bologna, Bologna/Italia.

49 ²⁴ Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of
50 Rome/Italy.

51 ²⁵ Department of Cellular Therapies and Transfusion Medicine, Careggi University Hospital,
52 Florence/Italy.

53 ²⁶ Ematologia e Centro Trapianti, IRCCS Ospedale Policlinico San Martino, Genova/Italy.

54 ²⁷ Istituti Clinici Scientifici Maugeri, Pavia/Italy.

55

56

57

58 Co-investigators for the Italian-BMT Study Group: Repice AM, Barilaro A, Capobianco M, Zimatore
59 GB, Frau J, Scarpini E, Meucci G, Guidetti D, Onofri M, Gualandi F, Varaldo R, Raiola AM, Innocenti C,
60 Zoli V, Ciceri F, Greco R, Scimè R, De Gobbi M

61

62

63

64

65

66

67

68 Disclosures

69 Boffa G was supported by a research fellowship-FISM Fondazione Italiana Sclerosi Multipla.

70 Signori A

71 Massacesi L

72 Mariottini A

73 Cottone S

74 Amato MP

75 Gasperini C

76 Moiola L

77 Meletti S

78 Brescia Morra V

79 Iaffaldano P

80 Salemi G

81 Patti F

82 Romeo M

83 De Luca G

84 Lus G

85 Zaffaroni M

86 Sola P

87 Conte A

88 Pozzilli C

89 Aguglia U

90 Granella F

- 91 Galgani S
- 92 Caniatti LM
- 93 Lugaresi A
- 94 Romano S
- 95 Saccardi R
- 96 Angelucci E
- 97 Mancardi GL
- 98 Sormani MP
- 99 Inglese M received grants NIH, NMSS, FISM; received fees for consultation from Roche, Genzyme,
100 Merck, Biogen and Novartis.
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113

114 Introduction

115 Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accrual of
116 neurological disability independent of clinical relapses(1). Compartmentalized inflammation within
117 the brain parenchyma(2–4) the leptomeninges(5) and the cerebrospinal fluid(6) represents a key
118 driver of disability worsening in SPMS. Persistent inflammation within the CNS, in terms of clinical
119 relapses or MRI activity, has been repeatedly associated with accelerated disability progression (7,8).
120 Although first randomized controlled clinical trials did not reveal the efficacy of disease-modifying
121 therapies (DMT) for disability progression during SPMS(9,10), a recent randomized clinical trial
122 established some benefits of siponimod(11,12) in reducing the risk of disability worsening compared
123 to placebo. In line with this result, observational studies have suggested that the use of available DMT
124 in SPMS may be therapeutically beneficial(13,14), especially in active SPMS(13). However, the overall
125 risk reduction in disability worsening with available DMT is only modest and it is still unclear whether
126 the effect of treatment persists over time.

127 Ablation of the immune system followed by autologous hematopoietic stem cell transplantation
128 (AHSCT) has been gain increasing evidence as a therapeutic strategy for refractory MS(15–17). AHST
129 eradicates autoreactive cell clones and induces sustained self-tolerance by resetting the abnormal
130 immune system(18). Although the ideal candidate of AHST is a young MS patient with aggressive
131 relapsing-remitting MS, uncontrolled evidence suggests that AHST is able to prevent long-term
132 neurological deterioration even in progressive MS(19–21). The drugs used in AHST technology cross
133 the blood-brain-barrier and penetrate into the CNS, with the potential to target compartmentalized
134 inflammation. Given the absence of satisfactory treatment options for SPMS, in the last two decades
135 AHST was used off-label for the treatment of 81 patients with aggressive SPMS in 14 Italian MS
136 centers.

137 The aim of this cohort study was to compare the effect of AH SCT on disability worsening in patients
138 with SPMS with that of other DMTs in SPMS patients from the Italian Multiple Sclerosis Register.

139

140 Methods

141 *Study Design*

142 All patients with SPMS(1), treated with AH SCT at 14 Italian MS Centers from 1997 to 2019 were
143 considered eligible for this study. Patients were treated according to the European Group for Blood
144 and Marrow Transplantation (EBMT) guidelines, following the decision of the treating physician and
145 approval of the local Ethics Committee. Although no formal guideline was used for patient selection,
146 patients had aggressive disease course, characterized by the occurrence of relapses, MRI
147 inflammatory activity or accrual of accelerated neurological disability despite active treatment.
148 Detailed information on conditioning regimen and transplant care is reported in the Supplementary
149 Materials.

150 Control patients with SPMS never treated with AH SCT were collected from the Italian MS
151 Register(22). Patients were considered eligible: a) if they had a baseline EDSS recording, b) at least
152 one follow-up visit and c) if a DMT had been started after the diagnosis of SPMS. Untreated patients
153 were included in a sensitivity analysis.

154

155 *Study endpoints*

156 The primary objective was to compare disability worsening as assessed by the EDSS score time course
157 after baseline in patients with SPMS treated with AH SCT versus those treated with other DMT.
158 Secondary endpoints were the cumulative proportion of patients with a 6-months confirmed
159 disability progression (CDP), defined as an increase of 1 point in the EDSS score (0.5 points if the

160 baseline EDSS score was ≥ 5.5), the cumulative proportion of patients with a 6-months confirmed
161 disability improvement (CDI), defined as a decrease of 1 point in the EDSS score (0.5 points if the
162 baseline EDSS score was ≥ 5.5) and the prevalence of disability improvement over time, defined as
163 the proportion of patients who are in an improved status as compared to baseline over time.

164

165 *Statistical methods*

166 Outcomes were compared between patients treated with AHST and patients treated with “other
167 DMT”. The “other DMT” group comprises all the patients satisfying the inclusion criteria and starting
168 any DMT during their follow up. Untreated patients were excluded from the analysis and included in
169 a sensitivity analysis. Descriptive results were reported as mean with standard deviation (SD) or
170 median with interquartile range (IQR) or range.

171 We applied two different propensity score (PS) approaches to mitigate the differences of baseline
172 characteristics between the treatment groups. First, we matched individual patients on their
173 propensity to receive AHST or one of the other DMT. Patients were matched without replacement
174 with a variable ratio up to 5:1 (other DMT : AHST) and using a nearest neighbor matching within a
175 caliper of 0.25 SDs of the PS. Second, we applied an overlap weighting (OW) approach(23). This
176 method has the advantage over the n:1 PS matching method that no patients are excluded from the
177 analysis, without modifying the target population(23). The OW method assigns to each patient a
178 weight proportional to the probability of that patient belonging to the opposite treatment group(23).
179 In our analysis, AHST treated patients are therefore weighted by the probability to receive one of
180 the other DMT (1-PS) and patients treated with other DMT are weighted by the probability of
181 receiving AHST treatment (PS). OW leads to an exact balance on the mean of each baseline covariate
182 included in the PS calculation.

183 For both methods, individual PS were calculated using a multivariable logistics regression model
184 including age at treatment start, gender, EDSS at treatment start, number of previous DMT, ARR in
185 the previous year, disease duration and year of treatment start. Only main effects, without
186 interactions, were included in the regression model. Since MRI data were missing for most of the
187 patients, they were not included in the primary PS calculation. A sensitivity analysis was run by
188 adjusting for a PS including MRI variables. Positivity assumption of PS was checked after its
189 calculation.

190 To assess the degree of unbalance of covariate distribution between the groups, Cohen's
191 standardized mean differences (SMD) were calculated in the original cohort and after matching or
192 weighting. A SMD < 0.10 was considered an acceptable balance.

193 All regression models were run on the matched cohorts or weighted according to PS. A linear mixed
194 model with random intercept and random slope was used to assess the longitudinal EDSS time trend
195 after baseline. A time*treatment group interaction term was included into the model to test
196 differences on EDSS time trend between the two treatment groups. Results were reported as
197 annualized EDSS change with 95% Confidence Intervals (CI). Differences between treatment groups
198 on time to CDP and CDI were assessed by mean of proportional hazard Cox regression models. Results
199 were reported as hazard-ratio (HR) with the corresponding 95% CI. Progression-free survival and
200 cumulative probability of improvement were estimated by Kaplan-Meier approach and graphically
201 displayed. The prevalence of CDI was estimated according to the recently reported methodology(24)
202 and compared between groups by bootstrapping the area under the curve (AUC). Stata (v.16;
203 StataCorp) was used for the computation.

204

205 *Sensitivity analyses*

206 The following sensitivity analyses were performed:

207 i) Inclusion of untreated patients in the “other DMT” group.

208 ii) Application of marginal structural models (MSM) to account for potential attrition bias
209 derived by a different duration of on-treatment follow-up in the matched groups. We
210 estimated at each 1-year time point the stabilized weights, from the inverse probability to be
211 censored at fixed timepoints conditional on baseline variables. Then we run a weighted Cox
212 regression analysis.

213 iii) Inclusion of magnetic resonance imaging (MRI) activity in the PS calculation. Two analyses
214 were performed: one with missing data imputed before the PS calculation using multiple
215 imputation approach with a logistic regression model and ten imputations. The second
216 analysis used only the subset with complete MRI information.

217 iv) Comparisons between a) patients treated with AHST vs patients treated with Interferon beta
218 1-b and b) patients treated with AHST vs patients treated with Mitoxantrone using a
219 matching without replacement with a variable ratio up to 5:1 (DMT : AHST) with the same
220 rules previously described. These two treatments were the only two approved in Italy for
221 treatment of SPMS.

222

223 Results

224 **Figure 1S** reports the flowchart for SPMS patients’ selection and inclusion. The SPMS cohort treated
225 by AHST included 81 patients from 14 centers. Two patients did not have follow-up information and
226 were excluded from the analysis. Data on 8465 SPMS patients were extracted from the Italian
227 Registry. Of these, 4550 were excluded due to the lack of a baseline EDSS assessments, 851 because
228 of missing follow up EDSS data and 703 since their DMT start date was during RRMS. A total of 2361

229 patients were included in the analysis; of them 1975 (83.7%) started a DMT (“other DMT” group)
230 while 386 (16.3%) were never treated. **Table 1S** reports the demographic and clinical characteristics
231 of the three groups (AH SCT, other DMT, untreated). Patients in the “other DMT” group were older
232 and with a longer disease duration, a lower baseline EDSS and a lower ARR in the previous year as
233 compared to AH SCT patients. DMT used by SPMS patients were mainly Interferons (38%),
234 Azathioprine and Glatiramer acetate (both around 20%). The untreated group was made up of older
235 patients with similar disease duration and EDSS and lower ARR in the previous year as compared with
236 “other DMT” treated subjects. **Table 1** reports the same characteristics for the matched and the OW
237 weighted cohorts, showing that both matching and OW weighting consistently reduced the SMD
238 between the two groups. The mean follow-up of the matched cohort was 5.2 years, with a median
239 of 3.6 years (IQR:1.8-7.6 years).

240

241 *AH SCT vs “Other DMT” patients*

242 *Yearly EDSS change*

243 **Figure 1** reports the estimated slopes of the EDSS change in the two treatment groups: the mean
244 EDSS change over 10 years in the AH SCT cohort was estimated as -0.013 EDSS points per year (95%
245 CI:-0.087, 0.061 EDSS points per year) while in the “other DMT” cohort the mean EDSS change was
246 +0.157 EDSS points per year; 95% CI: 0.117, 0.196 EDSS points per year) and the difference was
247 statistically significant (p for time by treatment group interaction<0.001). Similar results were
248 observed by the OW analysis and the estimated slopes of EDSS change are showed in the
249 Supplementary **Figure 2S**. The estimated yearly EDSS change was -0.017 (95% CI: -0.099, 0.065) in
250 the AH SCT cohort and +0.18 (95% CI: 0.15, 0.21) in the “other DMT” cohort (p for time by treatment
251 group interaction < 0.001).

252 *Time to CDP*

253 The time to CDP was significantly longer in AHST patients as compared to the matched “other DMT”
254 group (HR= 0.50; 95% CI: 0.31, 0.81; p=0.005, **Figure 2**) . After 3 years, the proportion of patients free
255 from CDP was 58.1% (95% CI:50.3-64.9) in the “other DMT” group and 71.9% (95% CI: 58.5-81.5) in
256 the AHST group; after 5 years it was, 46.3% (95% CI: 37.4, 54.5) in the “other DMT” group and 61.7%
257 (95% CI: 47.5,73.1) in the AHST group.

258 Similar results were observed when the OW procedure was applied to the whole cohort (**Figure 3S**).

259 *EDSS Improvement*

260 **Figure 3A** shows the Kaplan-Meier curves for time to CDI. In the matched cohorts the improvement
261 rate was significantly higher in AHST patients as compared with the “other DMT” group (HR = 4.21;
262 95% CI: 2.42-7.33; p<0.001). After 1 year the cumulative proportion of patients who had at least an
263 improvement event was 30.2% (95% CI: 20.6,42.8) in AHST patients and 3.4% (95% CI: 1.6, 7.0) in
264 the “other DMT” group; after 3 years it was 38.8% (95% CI: 28.0,51.9) in AHST patients and 7.8%
265 (95% CI: 4.2,13.3) in the “other DMT” group . AHST patients showed also a higher prevalence of
266 improvement (**Figure 3B**) over time (p < 0.001) as compared with the matched control group. The
267 proportion of patients who reached and maintained an improvement status after 3 years was 34.7%
268 (95% CI: 23.2,46.3) in the AHST group, while it was just 4.6% (95% CI: 1.7, 8.6) in the “other DMT”
269 group; after 5 years 18.7% (95% CI: 7.9,29.8) of AHST patients are still improved as compared to
270 baseline vs 4.1% (95% CI: 1.3,8.3) of patients treated with other DMTs.

271

272 *Sensitivity analyses*

273 *Inclusion of untreated patients*

274 Untreated patients were added to the cohort of patients treated with other DMT. A total of 72 AHST
275 patients were matched to 228 patients in the control group (26 untreated, 11.4% and 202 treated,
276 88.6%). Characteristics of matched patients are reported in **Table 2S**.

277 **Figure 4S** shows the results of the analysis on EDSS change. Results were similar to those reported in
278 the main analysis: the EDSS increased in the control group (yearly change +0.125; 95% CI: 0.099,0.151
279 EDSS points) while it was substantially stable in the HSCT group (yearly change +0.017 EDSS points;
280 95% CI: -0.032,0.066) with a significant difference between the two groups ($p < 0.001$). Results on
281 time to EDSS progression were very close to those reported in the main analysis (**Figure 5S**).

282 *Marginal structural model*

283 Results of the analysis run by applying MSM to the matched cohort (69 HSCT vs 217 other DMTs)
284 confirmed those reported in the main analysis. The time to CPD was significantly longer in HSCT
285 patients as compared to the “other DMT” group (HR= 0.58; 95% CI: 0.35, 0.96; $p=0.032$).

286 *Magnetic resonance (MRI) activity in the propensity score*

287 Data on MRI activity were available for 73/79 (92.4%) patients in the AHST group and for 812/1975
288 (41.1%) in the “other DMT” group. AHST group had a higher frequency (51/73; 70%) of MRI active
289 scans (defined as scans with at least 1 Gadolinium enhancing lesion) than the “other DMT” group
290 (156/812; 19.2%; **Table 1S**). After multiple imputation of missing values, 79 HSCT patients were
291 matched to 135 patients in the “other DMT” group. The two groups were well balanced (**Table 3S**).
292 Results on the primary outcome were similar to those reported in the main analysis: the EDSS
293 increased in the control group (yearly change +0.145; 95% CI: 0.115,0.175 EDSS points) while it was
294 substantially stable in the HSCT group (yearly change +0.015 EDSS points; 95% CI: -0.034,0.064) with
295 a significant difference between the two groups ($p < 0.001$). In the complete cases analysis, 71 HSCT

296 were matched to 100 “other DMT” and similar results were observed (EDSS points yearly change
297 +0.127; 95% CI: 0.091,0.164 in “other DMT” group vs 0.015; 95% CI: -0.038, 0.068 in HSCT; p = 0.001).

298 *HSCT vs Interferon beta-1b*

299 A total of 56 HSCT patients were matched with 63 Interferon beta-1b patients (**Table 4S**). Results
300 were similar to those reported for the analysis on “other DMTs”. In fact we observed an EDSS points
301 yearly change of +0.126; 95% CI: 0.078,0.174 in Interferon beta group and of 0.047; 95% CI: -0.011,
302 0.106 in HSCT with a significant difference between the two groups (p=0.040).

303 *HSCT vs Mitoxantrone*

304 A total of 74 HSCT patients were matched with 138 Mitoxantrone patients (**Table 4S**). Also for this
305 comparison on the primary outcome, results were similar to those reported previously. An EDSS
306 points yearly change of +0.129; 95% CI: 0.103,0.155 in Mitoxantrone group and of 0.023; 95% CI: -
307 0.025, 0.072 in HSCT with a significant difference between the two groups (p<0.001).

308

309 Discussion

310 To date, no prospective clinical trial has been performed to evaluate the efficacy of AHST in SPMS.
311 In this study, we showed that the use of AHST for the treatment of SPMS was associated with better
312 disability outcomes than other DMT. Despite treatment with active DMT, our SPMS control group
313 exhibited a mean disability accumulation of 0.16 EDSS points per year, with rates of CDP in line with
314 those reported by other independent cohorts(14,25). Conversely, treatment with AHST induced an
315 average improvement of EDSS over time (-0.013 EDSS points per year). This result translates into a
316 significant delayed time to first CDP in AHST patients compared to matched controls, with a
317 percentage of patients without CPD at 5 years of 61.7%.

318 Taken together, our findings confirm and extend the results of previous uncontrolled studies which
319 suggested that AHCT has the potential to slow down neurological progression in patients with
320 SPMS(19–21,26). AHCT has demonstrated a striking effect in abolishing clinical relapses and MRI
321 signs of inflammatory activity(19,27–32), which have been associated with worse outcomes during
322 the course of SPMS(7,13). Accordingly, it has been demonstrated that AHCT is able to reduce CSF
323 markers of ongoing CNS inflammation and axonal damage(33). The profound anti-inflammatory
324 effect of AHCT has been confirmed by pathological studies of MS lesions of patients with
325 SPMS(34,35), in which a dramatic decrease in T and B cells infiltrates has been described up to 7
326 years(35). Although residual demyelination and neurodegeneration have been reported after AHCT
327 (34,35), it is arguable that the almost complete resolution of compartmentalized inflammation
328 behind the blood–brain barrier obtained with AHCT has the potential to slow down disability
329 worsening in patients with SPMS, as suggested by the positive results of anti-inflammatory B-cell
330 targeted therapies in progressive MS(36,37). In line with this hypothesis, it has been demonstrated
331 that anti-inflammatory DMT could also reduce axonal damage in patients with SPMS(38–41),
332 potentially preventing disability accumulation.

333

334 We have previously reported that superimposed relapses(19) and inflammatory activity at baseline
335 MRI(20) are favorable predictors of a better outcome after AHCT in patients with SPMS. Similar
336 results have been reported in other cohorts of patients with SPMS(13), in which the effect of
337 immunotherapy in reducing disability progression was significant only in patients with active SPMS.
338 Therefore, it is still unknown whether immunotherapy, including AHCT, can be effective in patients
339 with SPMS without evidence of inflammatory activity. On the other hand, the results of this study

340 support the notion that the presence of inflammation during SPMS represents a treatable target and
341 requires adequate treatment.

342

343 A very intriguing result was that patients who underwent AHST were more likely to experience a
344 sustained disability improvement. Our data indicate that 18.7% of SPMS patients maintained an
345 improvement (a lower EDSS than baseline) 5 years after transplant, compared to the 4.1% of patients
346 treated by other DMT. The possibility to improve in disability and maintain improvement is a crucial
347 need for patients with a progressive disease, and it is hardly obtained with standard anti-
348 inflammatory drugs .

349

350 Notably, our SPMS control group did not include patients treated with siponimod or rituximab. In the
351 EXPAND study(11), siponimod treatment was associated with a delayed time to CDP than placebo,
352 with CDP rate of 23% over 3 years. Similar results have been published following treatment with
353 rituximab in SPMS(14), with CDP rates of 25% and 50% over 3 and 10 years, respectively. Baseline
354 characteristics of these studies were quite balanced, with evidence of MRI inflammatory activity and
355 relapses in the year before treatment start in about 20% of patients. Although our cohort was
356 composed by younger patients with a higher baseline ARR, it is noteworthy that the rate of CDP at
357 10 years was significantly lower in patients treated with AHST than in patients treated with
358 rituximab.

359

360 Limitations

361 The main limitation of the present study relies on its observational nature. Since our AHST study
362 cohort was composed mainly by patients with aggressive, active SPMS and did not represent a

363 standard population of patients with SPMS, we controlled for multiple demographic and clinical
364 variables to mitigate treatment selection bias. The superiority of AHST on disability outcomes was
365 confirmed using both the propensity score matching and the overlap weighting (in which no patients
366 are excluded from the analysis, without modifying the target population). As sensitivity analysis, we
367 also included untreated patients with SPMS and confirmed the protective effect of AHST on
368 disability worsening and time to CDP. The same results were obtained after the inclusion of measures
369 of MRI activity in the propensity score calculation and from the application of marginal structural
370 models to account for potential attrition bias derived by a different duration of on-treatment follow-
371 up in the matched groups. The superiority of AHST was also confirmed when considering as a control
372 group patients treated with interferon beta 1b and mitoxantrone, which were the only two DMTs
373 approved for the treatment of SPMS at the time of data collection of this study. Finally, although the
374 EDSS raters were not blinded to the treatment and this could have introduced some bias, the long-
375 term follow-up has partially mitigated this measurement bias.

376

377 Conclusions

378 AHST induced a marked slowing of disability progression in patients with active SPMS as compared
379 to other DMT. Prospective randomized clinical trials are needed to confirm the efficacy of AHST in
380 patients with active SPMS.

381

382 Bibliography

383

- 384 1. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the
385 clinical course of multiple sclerosis: The 2013 revisions. Neurology [Internet]. 2014 Jul

- 386 15;83(3):278–86. Available from:
- 387 <http://www.neurology.org/cgi/doi/10.1212/WNL.0000000000000560>
- 388 2. Luchetti S, Fransen NL, van Eden CG, Ramaglia V, Mason M, Huitinga I. Progressive multiple
389 sclerosis patients show substantial lesion activity that correlates with clinical disease severity
390 and sex: a retrospective autopsy cohort analysis. *Acta Neuropathol* [Internet]. 2018 Apr
391 13;135(4):511–28. Available from: <http://link.springer.com/10.1007/s00401-018-1818-y>
- 392 3. Machado-Santos J, Saji E, Tröscher AR, Paunovic M, Liblau R, Gabriely G, et al. The
393 compartmentalized inflammatory response in the multiple sclerosis brain is composed of
394 tissue-resident CD8+ T lymphocytes and B cells. *Brain* [Internet]. 2018 Jul 1;141(7):2066–82.
395 Available from: <https://academic.oup.com/brain/article/141/7/2066/5032773>
- 396 4. Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, Kornek B, Kasprian G, et al. Long-term
397 evolution of multiple sclerosis iron rim lesions in 7 T MRI. *Brain* [Internet]. 2021 Jan 23;
398 Available from: [https://academic.oup.com/brain/advance-](https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaa436/6114694)
399 [article/doi/10.1093/brain/awaa436/6114694](https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaa436/6114694)
- 400 5. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles
401 in secondary progressive multiple sclerosis associate with early onset of disease and severe
402 cortical pathology. *Brain* [Internet]. 2006 Nov 21;130(4):1089–104. Available from:
403 <https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awm038>
- 404 6. Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, et al. Inflammatory
405 intrathecal profiles and cortical damage in multiple sclerosis. *Ann Neurol* [Internet]. 2018
406 Apr;83(4):739–55. Available from: <http://doi.wiley.com/10.1002/ana.25197>
- 407 7. Paz Soldan MM, Novotna M, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, et al. Relapses and
408 disability accumulation in progressive multiple sclerosis. *Neurology* [Internet]. 2015 Jan

409 6;84(1):81–8. Available from:

410 <http://www.neurology.org/cgi/doi/10.1212/WNL.0000000000001094>

411 8. Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, et al. Association of Chronic Active
412 Multiple Sclerosis Lesions With Disability In Vivo. *JAMA Neurol* [Internet]. 2019 Dec
413 1;76(12):1474. Available from:
414 <https://jamanetwork.com/journals/jamaneurology/fullarticle/2747565>

415 9. Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on
416 disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3,
417 randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet*
418 *Neurol* [Internet]. 2018 May;17(5):405–15. Available from:
419 <https://linkinghub.elsevier.com/retrieve/pii/S1474442218300693>

420 10. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in
421 primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind,
422 placebo-controlled trial. *Lancet* [Internet]. 2016 Mar;387(10023):1075–84. Available from:
423 <https://linkinghub.elsevier.com/retrieve/pii/S0140673615013148>

424 11. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in
425 secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3
426 study. *Lancet* [Internet]. 2018 Mar;391(10127):1263–73. Available from:
427 <https://linkinghub.elsevier.com/retrieve/pii/S0140673618304756>

428 12. Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, et al. Siponimod and Cognition
429 in Secondary Progressive Multiple Sclerosis. *Neurology* [Internet]. 2021 Jan 19;96(3):e376–86.
430 Available from: <http://www.neurology.org/lookup/doi/10.1212/WNL.00000000000011275>

431 13. Lizak N, Malpas CB, Sharmin S, Havrdova EK, Horakova D, Izquierdo G, et al. Association of

- 432 Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary
433 Progressive Multiple Sclerosis. *JAMA Neurol* [Internet]. 2020 Nov 1;77(11):1398. Available
434 from: <https://jamanetwork.com/journals/jamaneurology/fullarticle/2768700>
- 435 14. Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, et al. Association
436 of Rituximab Treatment With Disability Progression Among Patients With Secondary
437 Progressive Multiple Sclerosis. *JAMA Neurol* [Internet]. 2019;1–8. Available from:
438 <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2018.4239>
- 439 15. Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R. Autologous Hematopoietic
440 Stem Cell Transplant in Multiple Sclerosis. *JAMA Neurol* [Internet]. 2020 Oct 26; Available
441 from: <https://jamanetwork.com/journals/jamaneurology/fullarticle/2771920>
- 442 16. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, et al. Autologous
443 Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis:
444 Position Statement from the American Society for Blood and Marrow Transplantation. *Biol*
445 *Blood Marrow Transplant* [Internet]. 2019 May;25(5):845–54. Available from:
446 <https://linkinghub.elsevier.com/retrieve/pii/S1083879119301399>
- 447 17. Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous
448 haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and
449 immune-mediated neurological diseases: updated guidelines and recommendations from the
450 EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc. Bone Marrow
451 Transplant [Internet]. 2020 Feb 26;55(2):283–306. Available from:
452 <http://www.nature.com/articles/s41409-019-0684-0>
- 453 18. Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous
454 haematopoietic stem cell transplantation for treatment of multiple sclerosis. *Nat Rev Neurol*.

455 2017;13(7):391–405.

456 19. Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, et al. Long-term Clinical
457 Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. *Neurology*
458 [Internet]. 2021 Feb 23;96(8):e1215–26. Available from:
459 <http://www.neurology.org/lookup/doi/10.1212/WNL.00000000000011461>

460 20. Mariottini A, Filippini S, Innocenti C, Forci B, Mechi C, Barilaro A, et al. Impact of autologous
461 haematopoietic stem cell transplantation on disability and brain atrophy in secondary
462 progressive multiple sclerosis. *Mult Scler J* [Internet]. 2020 Feb 3;135245852090239. Available
463 from: <http://journals.sagepub.com/doi/10.1177/1352458520902392>

464 21. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, et al. Long-term Outcomes
465 After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. *JAMA Neurol*
466 [Internet]. 2017;74(4):459. Available from:
467 <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2016.5867>

468 22. Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, et al. The Italian multiple
469 sclerosis register. *Neurol Sci* [Internet]. 2019 Jan 13;40(1):155–65. Available from:
470 <http://link.springer.com/10.1007/s10072-018-3610-0>

471 23. Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics
472 Attributes of a Randomized Clinical Trial. *JAMA* [Internet]. 2020 Jun 16;323(23):2417. Available
473 from: <https://jamanetwork.com/journals/jama/fullarticle/2765748>

474 24. Signori A, Boffa G, Bovis F, Mariottini A, Repice A, Inglese M, et al. Prevalence of disability
475 improvement as a potential outcome for multiple sclerosis trials. *Mult Scler J* [Internet]. 2020
476 Jun 26;135245852093623. Available from:
477 <http://journals.sagepub.com/doi/10.1177/1352458520936236>

- 478 25. Cree BAC, Gourraud P-A, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, et al. Long-
479 term evolution of multiple sclerosis disability in the treatment era. *Ann Neurol* [Internet]. 2016
480 Oct;80(4):499–510. Available from: <http://doi.wiley.com/10.1002/ana.24747>
- 481 26. Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kurbatova KA, et al.
482 Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-
483 intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives. *Ann*
484 *Hematol*. 2015;94(7):1149–57.
- 485 27. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and
486 autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a
487 multicentre single-group phase 2 trial. *Lancet* [Internet]. 2016;388(10044):576–85. Available
488 from: [http://dx.doi.org/10.1016/S0140-6736\(16\)30169-6](http://dx.doi.org/10.1016/S0140-6736(16)30169-6)
- 489 28. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of
490 Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying
491 Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis. *Jama*
492 [Internet]. 2019;321(2):165. Available from:
493 <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.18743>
- 494 29. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose
495 immunosuppressive therapy and autologous HCT for relapsing-remitting MS. *Neurology*.
496 2017;88(9):842–52.
- 497 30. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, et al. Autologous
498 haematopoietic stem cell transplantation for aggressive multiple sclerosis: The Swedish
499 experience. *J Neurol Neurosurg Psychiatry*. 2014;85(10):1116–21.
- 500 31. Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, et al. Prospective phase II

501 clinical trial of autologous haematopoietic stem cell transplant for treatment refractory
502 multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2019;90(5):514–21.

503 32. Kvistad SAS, Lehmann AK, Trovik LH, Kristoffersen EK, Bø L, Myhr K-M, et al. Safety and efficacy
504 of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. *Mult
505 Scler J* [Internet]. 2019 Dec 13;135245851989392. Available from:
506 <http://journals.sagepub.com/doi/10.1177/1352458519893926>

507 33. Larsson D, Åkerfeldt T, Carlson K, Burman J. Intrathecal immunoglobulins and neurofilament
508 light after autologous haematopoietic stem cell transplantation for multiple sclerosis. *Mult
509 Scler J*. 2019;(Dmd):1–9.

510 34. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al.
511 Autologous haematopoietic stem cell transplantation fails to stop demyelination and
512 neurodegeneration in multiple sclerosis. *Brain* [Internet]. 2007 Apr 2;130(5):1254–62.
513 Available from: <https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awl370>

514 35. Wundes A, Bowen JD, Kraft GH, Maravilla KR, McLaughlin B, von Geldern G, et al. Brain
515 pathology of a patient 7 years after autologous hematopoietic stem cell transplantation for
516 multiple sclerosis. *J Neurol Sci* [Internet]. 2017 Feb;373:339–41. Available from:
517 <https://linkinghub.elsevier.com/retrieve/pii/S0022510X17300163>


518 36. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus
519 Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med* [Internet]. 2017 Jan
520 19;376(3):209–20. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1606468>

521 37. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus
522 Teriflunomide in Multiple Sclerosis. *N Engl J Med* [Internet]. 2020 Aug 6;383(6):546–57.
523 Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1917246>

- 524 38. Romme Christensen J, Komori M, von Essen MR, Ratzler R, Börnsen L, Bielekova B, et al. CSF
525 inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture
526 residual inflammation associated with axonal damage. *Mult Scler J* [Internet]. 2019 Jun
527 18;25(7):937–46. Available from:
528 <http://journals.sagepub.com/doi/10.1177/1352458518774880>
- 529 39. Kapoor R, Smith KE, Allegretta M, Arnold DL, Carroll W, Comabella M, et al. Serum
530 neurofilament light as a biomarker in progressive multiple sclerosis. *Neurology* [Internet]. 2020
531 Sep 8;95(10):436–44. Available from:
532 <http://www.neurology.org/lookup/doi/10.1212/WNL.0000000000010346>
- 533 40. Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, et al.
534 Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. *Mult*
535 *Scler J* [Internet]. 2014 Jan 23;20(1):43–50. Available from:
536 <http://journals.sagepub.com/doi/10.1177/1352458513490544>
- 537 41. Kuhle J, Kropshofer H, Barro C, Meinert R, Häring DA, Leppert D, et al. Siponimod Reduces
538 Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients
539 (S8.006). *Neurology* [Internet]. 2018 Apr 10;90(15 Supplement):S8.006. Available from:
540 http://n.neurology.org/content/90/15_Supplement/S8.006.abstract

541

FIGURE 1



542

543

Table 1 – Clinical and demographic characteristics in the matched (left side) and in the overlap weighted (right side) groups

Characteristic	Matched cohort			Overlap weighted cohort		
	AHSCT (n=69)	Treated (n=217)	SMD AHSCT vs Treated	HSCT (n=79)	Treated (n=1975)	SMD HSCT vs Treated
Age, mean (SD); median (range)	38.1 (7.7); 37.1 (24-58)	37.8 (7.2); 37.2 (22-58)	0.037	39 (7.8); 37.5 (24-58)	39 (7.8); 38.4 (19-76)	0.001
Sex (M/F), n(%)	24/45 (34.8/65.2)	86/131 (39.9/60.1)	0.10	28/51 (35.5/64.5)	719/1256 (36.4/63.6)	0.001
Baseline EDSS, mean(SD); median (IQR)	6.2(0.9); 6.5(6-7)	6.3 (0.8); 6.5 (6-7)	0.076	6.2 (0.9); 6 (6-6.5)	6.2 (0.9); 6.5(6-7)	0.001
ARR previous year	1.08 (1.12)	0.90 (1.02)	0.17	1.01 (1.07)	1.01 (1.66)	0.001
Disease duration, mean (SD); median (IQR)	13.7 (6.5); 12.1 (10.1-16.5)	13.7 (6.1); 12.7 (9.3-17.8)	0.01	13.7 (6.8); 12.1 (10.1-17.3)	13.7 (6.6); 12.9 (9.3-18)	0.001
N. of previous treatments, mean (SD); median (IQR)	2.4 (1.2); 2 (1-3)	2.3 (1.4); 2 (1-3)	0.024	2.2 (1.1); 2 (1-3)	2.2 (1.4); 2 (1-3)	0.001
Year of treatment start,	2007.7 (6.4); 2007 (2002-2014)	2007.6 (5.3); 2007 (2004-2012)	0.019	2007.7 (6.2); 2007 (2003-2014)	2007.7 (5.4); 2008 (2004- 2012)	0.001

mean (SD); median (IQR)						
Year of SP conversion, mean (SD); median (IQR)	2005 (7.9); 2004 (1999- 2013); [n=53]	2005 (5.8); 2004 (2001- 2009)	0.011	2005 (7.9); 2004 (1999- 2013) [n=57]	2005 (6.1); 2005 (2001-2010)	0.00
Follow-up (years); median (IQR); range	6.8 (3.2-11.8); 0.1-20.1	3.1 (1.7-6.4); 0.1-18.4	-	5.6 (2.2- 11.1); 0.1- 20.1	3.9 (1.7-6.4); 0.1-30.9	-

544
545

Table 1S – Demographic and clinical characteristics of the three treatment groups.

Characteristics	HSCT (n=81)	Treated (n=1975)	Untreated (n=386)	SMD HSCT vs Treated	SM Un
Age, mean (SD); median (range)	37.8 (7.8); 36.8 (24- 58)	46.7 (9.6); 46.3 (19- 76)	50.2(11.1); 50 (20- 85)	1.02	1.2
Sex (M/F), n(%)	28/53 (34.6/65.4)	758/1217 (38.4/61.6)	125/261 (32.4/67.6)	0.096	0.0
Baseline EDSS, median (IQR); range	6.5 (6-6.5); 4-8.5	5.5 (4.5-6); 0-9	5.5(4-6.5); 0-9	0.86	0.8
ARR previous year	1.19 (1.27)	0.47 (0.77)	0.29 (0.61)	0.68	0.9
Disease duration, mean (SD); median (IQR)	13.3 (6.6); 11.8 (8.5- 16.3)	15.5 (8.7); 14.3 (9.2- 20.8)	16.6(10.1); 14.7(9.1-22.9)	0.29	0.4
N. of previous treatments, median (IQR); range	2 (1-3); 0-6	1 (0-1); 0-6	0 (0-1); 0-4	1.37	1.7
Year of treatment start, mean; median (IQR); range	2007.6; 2006 (2003- 2013); 1997-2019	2007.5; 2008 (2003- 2012); 1990-2018	-	0.012	-
Year of SP conversion, mean; median (IQR); range	2005; 2004 (2000- 2013); 1986-2018 [n=57]	2004; 2004 (2000- 2009); 1978-2017	2002.4; 2003(1997- 2009); 1977-2018	0.14	0.3
Treatments, n(%)*					
Interferon beta (IFN)	-	761 (38.5)	-		
Glatiramer acetate (GA)	-	424 (21.5)	-		
Fingolimod (FTY)	-	299 (15.1)	-		
Natalizumab (NTZ)	-	228 (11.5)	-		
Mitoxantrone (MIT)	-	360 (18.2)	-		
Azathioprine (AZA)	-	431 (21.8)	-		
Other	-	690 (34.9)	-		
N. of treatments received during follow-up					
1		1132 (57.3)			
2		555 (28.1)			
3		259 (13.1)			
4		29 (1.5)			
Time spent in treatment during follow-up (%)		95.7 (13.4); 100 (1.6- 100)			

546
547

Table 2S – Demographic and clinical characteristics of matched HSCT and Control group (treated and untreated) patients

Characteristics	HSCT (n=72)	Control (n=228)	SMD
Age, mean (SD)	38.5 (7.7)	39.5 (7.6)	0.12
Sex (M/F), n(%)	26/46 (35.6/64.4)	83/145 (36.4/63.6)	0.016
Baseline EDSS, mean (SD); median (IQR)	6.2 (0.9); 6.5 (6-6.5)	6.2 (0.9); 6 (6-6.5)	0.08
ARR previous year	1.05 (1.04)	0.76 (0.93)	0.29
Disease duration, mean (SD); median (IQR)	13.5 (6.7); 11.8 (10.1-16.5)	13.4 (6.2); 12.9 (8.9-17.1)	0.022
N. of previous treatments, median (IQR); range	2 (1-3); 0-5	2 (1-3); 0-6	0.19
Year of treatment start, mean; median (IQR)	2007.5; 2007 (2003-2014)	2007.6; 2008 (2004-2013)	0.027
Year of SP conversion, mean; median (IQR)	2005; 2004 (1999-2013) [n=54]	2005; 2006 (2001-2011)	0.061

548
549
550
551
552
553
554
555
556
557

Table 3S – Demographic and clinical characteristics of matched HSCT and other DMTs patients

Characteristics	HSCT (n=79)	Treated (n=135)	SMD
Age, mean (SD)	38.1 (7.7)	38.3 (7.5)	0.032
Sex (M/F), n(%)	27/52 (33.8/66.2)	50/85 (36.9/63.1)	0.066
Baseline EDSS, mean (SD); median (IQR)	6.3 (0.9); 6.5 (6-7)	6.4 (0.9); 6.5 (6-7)	0.18
ARR previous year	1.13 (1.21)	1.06 (1.06)	0.066
Disease duration, mean (SD); median (IQR)	13.4 (6.6); 11.8 (8.5-16.5)	13.6 (5.1); 12.9 (8.9-17.1)	0.032
N. of previous treatments, median (IQR); range	2 (1-3); 0-5	2 (1-3); 0-6	0.011
Year of treatment start, mean; median (IQR)	2007.6; 2006 (2003-2014)	2008.4; 2008 (2004-2013)	0.15
Year of SP conversion, mean; median (IQR)	2005; 2004 (2000-2013) [n=57]	2006; 2005 (2001-2011)	0.12

558
559
560
561
562
563
564
565
566
567

568
569
570

Table 4S – Demographic and clinical characteristics of matched HSCT and Interferon beta-1b (left side) or Mitoxantrone

Characteristics	HSCT (n=56)	Interferon beta-1b (n=63)	SMD	HSCT (n=74)	Mitoxantrone (n=138)
Age, mean (SD)	39.6 (7.6)	39.5 (6.6)	0.016	38.4 (7.6)	38.8 (6.4)
Sex (M/F), n(%)	23/33 (41/59)	29/34 (46/54)	0.10	27/47 (36.5/63.5)	35/103 (33.6/66.4)
Baseline EDSS, mean (SD); median (IQR)	6.2 (0.9); 6.5 (6-6.5)	6.3 (0.7); 6.5 (6-7)	0.11	6.3 (0.9); 6.5 (6-7)	6.4 (0.9)
ARR previous year	0.76 (0.79)	0.60 (0.73)	0.20	1.05 (1.07)	0.97 (1.1)
Disease duration, mean (SD); median (IQR)	13.9 (6.9); 12.3 (10.4-17.5)	14.6 (6.9); 14.4 (9.7-18.9)	0.086	13.5 (6.8); 11.9 (8.5-17.3)	13.3 (5.5); 11.9 (8.7-16.3)
N. of previous treatments, median (IQR); range	2 (1-3); 0-4	2 (2-3); 0-5	0.059	2 (1-3); 0-6	2 (2-3); 0-10
Year of treatment start, mean; median (IQR)	2007; 2006 (2002-2013)	2005; 2005 (2000- 2007)	0.33	2007; 2006 (2002-2012)	2006; 2006 (2000-2008)
Year of SP conversion, mean; median (IQR)	2004; 2004 (1998-2010) [n=42]	2000; 2000 (1998-2002)	0.62	2004; 2004 (1999-2011)	2003; 2003 (2000-2005)

571
572